Fellowship · New York, NY
Sponsored by NYU Grossman School of Medicine
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England) · 2022 · 231 citations · Mercedes Gonzalez
Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders.
JAMA dermatology · 2024 · 54 citations · Raegan Hunt
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
JAMA dermatology · 2024 · 56 citations · Mercedes Gonzalez
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
The New England journal of medicine · 2022 · 150 citations · Mercedes Gonzalez
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.
JAMA dermatology · 2024 · 31 citations · Seth Orlow
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Dermatitis : contact, atopic, occupational, drug · 2026 · 12 citations · Mercedes Gonzalez
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
Pediatric dermatology · 2025 · 19 citations · Mercedes Gonzalez
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.
American journal of clinical dermatology · 2025 · 14 citations · Mercedes Gonzalez